By Pooja Toshniwal PahariaJun 19 2023Reviewed by Danielle Ellis, B.Sc. In a recent study in Vaccine, researchers described simultaneous vaccination with primary series severe acute respiratory syndrome coronavirus 2 vaccines. They assessed 23 pre-determined health outcomes following SV among individuals aged five years and above in the Vaccine Safety Datalink .
Previous observational studies and clinical trials underpin simultaneous vaccinations. However, a few studies have reported increased risks of adverse events among individuals receiving SV with non-SARS-CoV-2 vaccines, e.g.
SV was described as the receipt of any non-SARS-CoV-2 vaccine on the day of the first or second doses of the primary SARS-CoV-2 vaccines, following the Advisory Committee on Immunization Practices guidelines. The vaccines were administered at different anatomical sites and not combined in the same syringe. Simultaneously administered vaccines were grouped to form mutually exclusive groups; e.g., all types of influenza vaccines were grouped into the “All Influenza” group.
Related StoriesAdverse events were rare following simultaneous vaccination with SARS-CoV-2 vaccines, with only 56 outcomes reported after the first and second doses. The adverse event rates among SV recipients SV did not differ significantly from that among non-SV recipients .
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: NewsMedical - 🏆 19. / 71 Read more »
Source: NewsMedical - 🏆 19. / 71 Read more »